SANTEN-PHARMACEUTICAL
26.7.2021 09:02:06 CEST | Business Wire | Press release
Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to implement United Nations General Assembly Resolution A/75/L.108 on eye health. This comes after several months of collaboration with the IAPB, advocating for global action to improve access to basic eye health services.
Santen is committed to reducing the loss of social and economic opportunities for people living with eye conditions. The new UN General Assembly resolution encourages governments and key stakeholders from around the world to mobilize the necessary resources to address this urgent priority. UN entities including UNICEF, UN-Women, UNDP, UNESCO, the International Labor Organization and the UN Road Safety Collaboration will work to promote and include eye health in their work. International financial institutions and donors will be urged to include eye health priorities in their funding programs. We take the adoption of this resolution as an opportunity to further enhance our policy and advocacy activities with the IAPB.
“The eye health sector has believed for a long time that quality eye care is critical to the world achieving the Sustainable Development Goals” said Peter Holland, CEO of IAPB. “IAPB and its members are committed to supporting governments to implement this resolution and ensure that no one is left behind”.
To support the implementation of this resolution, Santen and the IAPB will work together on a number of initiatives as part of their ongoing strategic partnership , including:
- Partnership with national governments and supranational stakeholders to establish an effective monitoring system and encourage the inclusion of eye health in voluntary national reporting on the Sustainable Development Goals (SDGs).
- Coordination of an advocacy and public affairs strategy to lobby for the inclusion of two eye health targets in the next review of the SDGs by the UN Inter-Agency Expert Group in 2025.
Today, 1.1 billion people are living with preventable sight loss due to a lack of access to basic eye care services. With appropriate allocation of resources and investment for the early detection and treatment of eye conditions, including disease awareness campaigns and regular eye tests, sight can be protected.1 Vision loss can have a significant detrimental impact on quality of life (QOL), including depression, discomfort and social isolation. Improving access to eye care services therefore, has the potential to improve the QOL for millions of people.2 Additionally, sight loss is calculated to cost the global economy $411bn in productivity each year, showing it has tremendous economic consequences3 . Eye health is directly linked to more than half of the sustainable development goals (SDGs), including eliminating poverty and hunger, improving education, and gender equality4 . Therefore, a “whole of government approach” to eye care and strengthened collaboration between stakeholders is necessary to ensure the people living with preventable sight loss receive access to support and treatment.
“The adoption of UN resolution on eye health represents a major leap towards the realization of our WORLD VISION (Happiness with Vision)” said Shigeo Taniuchi, President & CEO of Santen, “There is ample evidence that eye health is a global development issue. About 90% of preventable vision loss occurs in low and middle income countries, of which 55% affects women and girls. People, in general, receive 80% of information visually and eye disease tend to be chronic, affecting patients’ quality of life. As a specialized company dedicated to ophthalmology, we are committed to promoting international efforts on eye health and contributing to the realization of the SDGs. Supporting the implementation of this resolution is a crucial step towards facilitating access to eye care services and reducing the loss of social and economic opportunities for people around the world due to eye conditions”.
References:
- International Agency for the Prevention of Blindness (IAPB). Vision Atlas. Available here: https://www.iapb.org/learn/vision-atlas
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
About Santen
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.
Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.
With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen’s website (www.santen.com
).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005246/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 16:30:00 CEST | Press release
Companies team to deliver a unified, enterprise-scale agentic stack to help organizations with managing data sovereignty and optimizing AI costs Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
